Vivimed Labs gains on zero 483 observations from USFDA: 7 June 2017

vivimed

 

Vivimed Labs rallied 7% to Rs 112 on the BSE in early morning trade after the US health regulator recently inspected the company’s manufacturing plant in Spain and did not issue any observations.

The company’s active pharmaceutical ingredient (API) manufacturing facility located at Sant Celoni, Spain, was recently inspected by the United States Food and Drug Administration (USFDA).

At the end of the successful inspection, ‘zero’ 483 observations were issued. This was a routine inspection by the USFDA, Vivimed Labs said in a release.

At 09:28 am; the stock was up 6% at Rs 111.65 on BSE as compared to 0.24% rise in the S&P BSE Sensex. A combined 782,310 shares changed hands on the counter on BSE and NSE so far.

Capitalstars Financial Research Private Limited is a research house and an investment advisory carrying out operations in the Indian Equities and Commodity market.We also provide 2 days free trial to our client.Join our services and trade with us.

GET MORE DETAILS HERE:-
Commodity Market Tips

Nifty Future Tips

* INVESTMENT & TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISKS, PAST PERFORMANCE IS NOT A GUARANTEE OF FUTURE PERFORMANCE.
* CAPITALSTARS INVESTMENT ADVISER: SEBI REGISTRATION NUMBER: INA000001647
Advertisements